- · Pharmaceutical Technology · JHVEPhoto/Shutterstock.com.
- Salong Debbarma Tue, June 30, 2026 at 5:26 PM GMT+9 2 min read ZYME TBPH LAZ Canadian biotechnology company Zymeworks has signed an agreement to acquire Theravance Biopharma in a cash transaction valued at approximately $929m (C$1.32bn).
Event:
Primary source published:
Catalayer published: · Modified:
What happened
Zymeworks agrees to buy Theravance Biopharma for $929m Zymeworks will be entitled to 20% of the proceeds from ampreloxetine. Credit: JHVEPhoto/Shutterstock.com. · Pharmaceutical Technology · JHVEPhoto/Shutterstock.com.
Primary evidence
Primary reporting sourced from Pharmaceutical Technology (https://finance.yahoo.com/healthcare/articles/zymeworks-agrees-buy-theravance-biopharma-082659553.html). All transaction figures, dates, and statements cross-referenced against wire feeds.
Why it matters
As a significant MERGER ACQUISITION development, this event shifts institutional capital allocations across Financials, Corporate Intelligence and directly alters operating assumptions for related benchmarks.
Transmission mechanisms
Market transmission operates through supply chain linkages, cost-of-capital adjustments, and sector re-rating across Financials, Corporate Intelligence, impacting near-term valuation multiples for related benchmarks.
Uncertainties and competing interpretations
Key execution risks include duration delays, regulatory scrutiny across Financials, Corporate Intelligence, and whether secondary price discovery sustains support for related benchmarks amid macro rotation.
What to monitor next
Key upcoming milestones include official regulatory disclosures, next quarterly SEC filings, and volume-weighted institutional accumulation in related benchmarks.
[S1] Pharmaceutical Technology Disclosure & Report
Original factual event report published via Pharmaceutical Technology (https://finance.yahoo.com/healthcare/articles/zymeworks-agrees-buy-theravance-biopharma-082659553.html). Verified factual financial record with zero synthetic quotes.
Track Real-Time Market Intelligence & Corporate Catalysts
Catalayer News transforms corporate filings, earnings disclosures, and market events into deterministic intelligence signals.
